Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV

PharmacoEconomics

Volumn 28, Issue 11, 2010, Pages 1025-1039

  Kauf, Teresa L ^a   Farkouh, Raymond A ^b   Earnshaw, Stephanie R ^b   Watson, Maria E ^c   Maroudas, Penny ^d   Chambers, Mike G ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

abacavir; cost effectiveness; cost utility; genetic screening; HIV infections; hypersensitivity; research and development; tenofovir; therapeutic use; treatment

Indexed keywords

ABACAVIR; EFAVIRENZ; EMTRICITABINE; HLA B ANTIGEN; LAMIVUDINE; LOPINAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG USE; GENETIC SCREENING; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; KIDNEY FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION TREES; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; DRUG TOXICITY; GENETIC TESTING; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; PHOSPHONIC ACIDS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 77958005168     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11535540-000000000-00000     Document Type: Article

References (29)

1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001 Oct; 23(10):1603-14
2. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002 Oct; 24(10):1502-14
3. Hetherington S, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir: retrospective analysis of 25 clinical trials [abstract no. 527]. IAS Conference on HIV Pathogenesis and Treatment; 2001 Jul. 8-11; Buenos Aires
4. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002 Mar. 2; 359(9308):727-32
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville (MD): Department of Health and Human Services, 2009 Dec. 1 [online]. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf [Accessed 2009 Jan 23]
6. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006 Jul. 1; 43(1):99-102
7. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b *5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008 Apr. 1; 46(7):1111-8
8. Zucman D, Truchis P, Majerholc C, et al. Prospective screening for human leukocyte antigen-B *5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007 May 1; 45(1):1-3
9. Mallal S, Phillips E, Carosi G, et al. HLA-B *5701 screening for hypersensitivity to abacavir. N Engl J Med 2008 Feb. 7; 358(6):568-79
10. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008 Oct; 9(8):563-608
11. Hammer SM, Eron Jr JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008 Aug. 6; 300(5):555-70
12. Schackman BR, Scott CA, Walensky RP, et al. The costeffectiveness of HLA-B *5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008 Oct. 1; 22(15):2025-33
13. Young B, Squires K, Patel P, et al. First large, multicenter, open-label study utilizing HLA-B *5701 screening for abacavir hypersensitivity in North America. AIDS 2008 Aug. 20; 22(13):1673-5
14. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2006 [online]. Available from URL: http://www.cdc.gov/hiv/topics/surveillance/ resources/reports [Accessed 2009 Jan 23]
15. Dejesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004 Oct. 1; 39(7):1038-46
16. Gallant JE, Dejesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006 Jan 19; 354(3):251-60
17. Eron Jr J, Yeni P, Gathe Jr J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006 Aug. 5; 368(9534):476-82
18. Johnson MA, Gathe Jr JC, Podzamczer D, et al. A oncedaily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006 Oct. 1; 43(2):153-60
19. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008 Jan 30; 22(3):385-93
20. Red book for Windows [computer program]. Montvale (NJ): Thomson PDR, 2007
21. LabCorp. HLA test [online]. Available from URL: http://www.labcorp.com/ datasets/labcorp/html/chapter/mono/hl002200.htm [Accessed 2007 Jul. 17]
22. Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule [online]. Available from URL: http://www.cms.hhs.gov/ ClinicalLabFeeSched/01-overview.asp [Accessed 2007 Jan 25]
23. Centers for Medicare and Medicaid Services. Medicare physician fee schedule [online]. Available from URL: http://www.cms.hhs.gov/PhysicianFeeSched/ 01-Overview.asp [Accessed 2007 Jan 25]
24. Ingenix. Integrated health care information services [online]. Available from URL: http://www.ingenix.com/AboutUs/Businesses/ihcis/[Accessed 2009 Jan 25]
25. Nordstrom BL, Norman HS, Dube TJ, et al. Identification of abacavir hypersensitivity reaction in health claims data. Pharmacoepidemiol Drug Saf 2007;16(3):289-96
26. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007 Jun. 19; 21(10):1273-81
27. Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health 2008 May 20; 11(7):1144-53
28. Bell CM, Chapman RH, Stone PW, et al. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 2001 Jul-Aug; 21(4):288-94
29. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B *5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004 Jun; 14(6):335-42